No abstract

Turnip (latin Brassica rapa) is a herbaceous plant from the genus Cruciferous. The root crop is a traditional product that has been producing in Russia since ancient times. This unpretentious herbaceous plant contains many different nutrients. The composition of turnips determines its value as a dietary product. From an economic point of view, the root crop, along with broccoli, can act as a source of biologically active substances like sulforaphane. Processing root crops using extraction will expand the scope of its application. The work presents a laboratory way for producing an extract of sulforaphane, followed by its quantitative determination from turnip varieties Petrovskaya-1. It was shown that the content of sulforaphane turnip extract (0.83 ± 0.03) mg in 1 cm3 extract. Next, the antioxidant ability of the extract was determined. A spectrophotometric study of antioxidant activity using a model adrenaline autooxidation reaction (in vitro) revealed that the aqueous extract has a pronounced antioxidant effect. It was registered that at an exposure time of 5 min, the AOA of the extract was 49.0%, at 10 min it was 13.0%. We can say that the processing of root crops is promising as a source of biologically active substances.

<div>Abstract<p>Glucocorticoids are widely used for therapy of hematologic malignancies. Unfortunately, chronic treatment with glucocorticoids commonly leads to adverse effects including skin and muscle atrophy and osteoporosis. We found recently that REDD1 (regulated in development and DNA damage 1) plays central role in steroid atrophy. Here, we tested whether REDD1 suppression makes glucocorticoid-based therapy of blood cancer safer. Unexpectedly, approximately 50% of top putative REDD1 inhibitors selected by bioinformatics screening of Library of Integrated Network-Based Cellular Signatures database (LINCS) were PI3K/Akt/mTOR inhibitors. We selected Wortmannin, LY294002, and AZD8055 for our studies and showed that they blocked basal and glucocorticoid-induced REDD1 expression. Moreover, all PI3K/mTOR/Akt inhibitors modified glucocorticoid receptor function shifting it toward therapeutically important transrepression. PI3K/Akt/mTOR inhibitors enhanced anti-lymphoma effects of Dexamethasone <i>in vitro</i> and <i>in vivo</i>, in lymphoma xenograft model. The therapeutic effects of PI3K inhibitor+Dexamethasone combinations ranged from cooperative to synergistic, especially in case of LY294002 and Rapamycin, used as a previously characterized reference REDD1 inhibitor. We found that coadministration of LY294002 or Rapamycin with Dexamethasone protected skin against Dexamethasone-induced atrophy, and normalized RANKL/OPG ratio indicating a reduction of Dexamethasone-induced osteoporosis. Together, our results provide foundation for further development of safer and more effective glucocorticoid-based combination therapy of hematologic malignancies using PI3K/Akt/mTOR inhibitors.</p></div>